ZNTL

SEC source: 0001725160-24-000186 · wk-form4_1731538012.xml · nonDerivative · entry 1

Myers Scott Dunseth · CIK 0001356256 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 260,192

F1 · shares: The restricted stock units ("RSUs") were granted by the Issuer pursuant to the Issuer's Non-Employee Director Compensation Program. One third of the RSUs will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.

SEC source: 0001725160-24-000163 · wk-form4_1728079274.xml · nonDerivative · entry 1

Vultaggio Vincent · CIK 0002018766 · Principal Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,855

F1 · kind: A portion of the shares were sold automatically to satisfy withholding tax obligations upon the vesting of restricted stock units, and the remainder of the shares were sold pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on September 20, 2023.

SEC source: 0001725160-24-000141 · wk-form4_1719004045.xml · nonDerivative · entry 1

Johnson David Michael · CIK 0001808098 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 192,818

F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 21, 2025 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

SEC source: 0001725160-24-000145 · wk-form4_1719004255.xml · nonDerivative · entry 1

Skvarka Jan · CIK 0001838042 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,551

F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 21, 2025 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

SEC source: 0001725160-24-000143 · wk-form4_1719004175.xml · nonDerivative · entry 1

Kariuki Enoch · CIK 0001843119 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,762

F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 21, 2025 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

SEC source: 0001725160-24-000127 · wk-form4_1717194425.xml · nonDerivative · entry 1

Gallagher Cam · CIK 0001557832 · Director · President, Interim CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 633,680

F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.

SEC source: 0001725160-24-000123 · wk-form4_1716982442.xml · nonDerivative · entry 1

Walker Luke Nathaniel · CIK 0001701440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,481

F1 · shares: The restricted stock units ("RSUs") were granted by the Issuer pursuant to the Issuer's Non-Employee Director Compensation Program. One third of the RSUs will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.

SEC source: 0001725160-24-000111 · wk-form4_1715298409.xml · nonDerivative · entry 1

HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 373,876

F1 · kind: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.

SEC source: 0001725160-24-000043 · wk-form4_1707787354.xml · nonDerivative · entry 1

Epperly Melissa B, · CIK 0001807359 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 451,449

F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person.

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.29 to $11.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001725160-24-000041 · wk-form4_1707787292.xml · nonDerivative · entry 1

Gallagher Cam · CIK 0001557832 · Director · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 643,277

F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person.

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.29 to $11.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001725160-24-000032 · wk-form4_1707178473.xml · nonDerivative · entry 2

Paul Andrea · CIK 0001863130 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 149,973

F2 · kind: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.35 to $11.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001725160-24-000028 · wk-form4_1707178346.xml · nonDerivative · entry 2

Epperly Melissa B, · CIK 0001807359 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 454,022

F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.35 to $11.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001725160-24-000034 · wk-form4_1707178516.xml · nonDerivative · entry 2

Lackner Mark · CIK 0001777413 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 195,728

F2 · kind: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.35 to $11.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001725160-24-000030 · wk-form4_1707178402.xml · nonDerivative · entry 2

Gallagher Cam · CIK 0001557832 · Director · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 644,450

F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.35 to $11.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001725160-24-000032 · wk-form4_1707178473.xml · derivative · entry 4

Paul Andrea · CIK 0001863130 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2034-01-31

F5 · derivative.exercise_date: The options were granted to the Reporting Person in connection with Reporting Person's promotion to Chief Legal Officer, which became effective February 1, 2024. The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001725160-24-000032 · wk-form4_1707178473.xml · derivative · entry 3

Paul Andrea · CIK 0001863130 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,500

Underlying: Common Stock · 112,500 shares

Expires 2034-01-31

F4 · derivative.exercise_date: The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. The options are Reporting Person's annual equity grants, which reflect the market data for Reporting Person's role as Chief Legal Officer, a role to which she was promoted on February 1, 2024.

SEC source: 0001725160-24-000032 · wk-form4_1707178473.xml · nonDerivative · entry 1

Paul Andrea · CIK 0001863130 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 153,283

F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001725160-24-000026 · wk-form4_1707178279.xml · derivative · entry 3

Blackwell Kimberly · CIK 0001816465 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2034-01-31

F3 · derivative.exercise_date: The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001725160-24-000026 · wk-form4_1707178279.xml · nonDerivative · entry 2

Blackwell Kimberly · CIK 0001816465 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 484,145

F2 · kind: Shares automatically withheld to satisfy tax obligations upon the vesting of restricted stock units previously granted to the Reporting Person.

SEC source: 0001725160-24-000026 · wk-form4_1707178279.xml · nonDerivative · entry 1

Blackwell Kimberly · CIK 0001816465 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 504,800

F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001725160-24-000028 · wk-form4_1707178346.xml · derivative · entry 3

Epperly Melissa B, · CIK 0001807359 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2034-01-31

F4 · derivative.exercise_date: The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001725160-24-000028 · wk-form4_1707178346.xml · nonDerivative · entry 1

Epperly Melissa B, · CIK 0001807359 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 462,691

F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001725160-24-000036 · wk-form4_1707178572.xml · derivative · entry 2

HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 337,500

Underlying: Common Stock · 337,500 shares

Expires 2034-01-31

F2 · derivative.exercise_date: The options were granted to the Reporting Person in connection with Reporting Person's previously disclosed appointment as Chief Medical Officer, effective January 19, 2024. The options will vest over four years in equal monthly installments from the vesting commencement date of January 19, 2024 until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001725160-24-000036 · wk-form4_1707178572.xml · nonDerivative · entry 1

HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 377,232

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person in connection with Reporting Person's previously disclosed appointment as Chief Medical Officer, effective January 19, 2024. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in substantially equal annual installments over a four year period following the vesting commencement date of January 19, 2024, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001725160-24-000034 · wk-form4_1707178516.xml · derivative · entry 3

Lackner Mark · CIK 0001777413 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,000

Underlying: Common Stock · 141,000 shares

Expires 2034-01-31

F4 · derivative.exercise_date: The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. The options are Reporting Person's annual equity grants, which reflect the market data for Reporting Person's role as Chief Scientific Officer, a role to which he was promoted on December 31, 2023.

SEC source: 0001725160-24-000034 · wk-form4_1707178516.xml · nonDerivative · entry 1

Lackner Mark · CIK 0001777413 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 197,313

F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001725160-24-000030 · wk-form4_1707178402.xml · derivative · entry 3

Gallagher Cam · CIK 0001557832 · Director · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 192,500

Underlying: Common Stock · 192,500 shares

Expires 2034-01-31

F4 · derivative.exercise_date: The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001725160-24-000030 · wk-form4_1707178402.xml · nonDerivative · entry 1

Gallagher Cam · CIK 0001557832 · Director · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 656,002

F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001725160-24-000004 · wk-form4_1704331256.xml · derivative · entry 2

Lackner Mark · CIK 0001777413 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2034-01-02

F2 · derivative.exercise_date: The options were granted to the Reporting Person in connection with Reporting Person's previously disclosed promotion to Chief Scientific Officer, which became effective December 31, 2023. The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001725160-24-000004 · wk-form4_1704331256.xml · nonDerivative · entry 1

Lackner Mark · CIK 0001777413 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,313

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person in connection with Reporting Person's previously disclosed promotion to Chief Scientific Officer, which became effective December 31, 2023. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the vesting commencement date of December 31, 2023, subject to the Reporting Person's continuing service with the Issuer.

SEC source: 0001725160-23-000203 · wk-form4_1703198862.xml · nonDerivative · entry 1

Bunker Kevin D. · CIK 0001807484 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 834,931

F1 · balance_after: The Reporting Person transferred 24,158 shares to the Raising Hope Foundation, a charitable foundation of which the Reporting Person is a director. The Reporting Person has voting and investment power over all securities owned by the Raising Hope Foundation.

SEC source: 0001725160-23-000200 · wk-form4_1699914229.xml · nonDerivative · entry 1

Blackwell Kimberly · CIK 0001816465 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 254,800

SEC source: 0001725160-23-000201 · wk-form4_1699914237.xml · nonDerivative · entry 1

Johnson David Michael · CIK 0001808098 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 144,389

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $9.70 to $9.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001725160-23-000180 · wk-form4_1696634351.xml · nonDerivative · entry 2

Bunker Kevin D. · CIK 0001807484 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 859,089

F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.91 to $19.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001725160-23-000180 · wk-form4_1696634351.xml · nonDerivative · entry 1

Bunker Kevin D. · CIK 0001807484 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 860,072

F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.91 to $19.90. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001725160-23-000181 · wk-form4_1696634381.xml · nonDerivative · entry 2

Brownstein Carrie · CIK 0001894232 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,685

F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.91 to $19.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001725160-23-000181 · wk-form4_1696634381.xml · nonDerivative · entry 1

Brownstein Carrie · CIK 0001894232 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 107,407

F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.91 to $19.90. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001725160-23-000179 · wk-form4_1696634321.xml · nonDerivative · entry 2

Epperly Melissa B, · CIK 0001807359 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 387,691

F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.

F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.91 to $19.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes 1,125 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on March 31, 2023.

SEC source: 0001725160-23-000179 · wk-form4_1696634321.xml · nonDerivative · entry 1

Epperly Melissa B, · CIK 0001807359 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 388,579

F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.91 to $19.90. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes 1,125 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on March 31, 2023.

SEC source: 0001725160-23-000162 · wk-form4_1694635867.xml · nonDerivative · entry 1

Skvarka Jan · CIK 0001838042 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,970

F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires September 14, 2023.

F2 · balance_after: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $24.76 to $25.28. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000902664-23-003642 · ownership.xml · nonDerivative · entry 1

Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner

GOEL DAVID E. · CIK 0001548144 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 13,959,973

F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC source: 0001725160-23-000146 · wk-form4_1686949452.xml · nonDerivative · entry 1

Johnson David Michael · CIK 0001808098 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 127,389

F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2024 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

SEC source: 0001725160-23-000143 · wk-form4_1686949344.xml · nonDerivative · entry 1

Kariuki Enoch · CIK 0001843119 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,181

F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2024 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

SEC source: 0001725160-23-000141 · wk-form4_1686949276.xml · nonDerivative · entry 1

Skvarka Jan · CIK 0001838042 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,970

F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2024 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

SEC source: 0001725160-23-000125 · wk-form4_1685581824.xml · nonDerivative · entry 2

Gallagher Cam · CIK 0001557832 · Director · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 463,502

F2 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023.

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $25.91 to $26.51. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001725160-23-000125 · wk-form4_1685581824.xml · nonDerivative · entry 1

Gallagher Cam · CIK 0001557832 · Director · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 482,028

F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.

SEC source: 0001725160-23-000124 · wk-form4_1685581781.xml · nonDerivative · entry 1

Bunker Kevin D. · CIK 0001807484 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 15,000

F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires July 31, 2023.

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $30.00 to $30.10. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any.

SEC source: 0001725160-23-000116 · wf-form4_168371718549282.xml · nonDerivative · entry 1

HAUSMAN DIANA · CIK 0001563992 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,732

F1 · shares: The restricted stock units ("RSUs") were granted by the Issuer pursuant to the Issuer's Non-Employee Director Compensation Program. One third of the RSUs will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.

SEC source: 0001725160-23-000050 · wf-form4_167779259154330.xml · derivative · entry 2

Roth Iris · CIK 0001964808 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 297,500

Underlying: Common Stock · 297,500 shares

Expires 2033-03-01

F2 · derivative.exercise_date: The options will vest over four years: 25% of the options will vest on February 6, 2024, with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001725160-23-000050 · wf-form4_167779259154330.xml · nonDerivative · entry 1

Roth Iris · CIK 0001964808 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,500

F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the vesting commencement date of Feb. 6, 2023, subject to the Reporting Person's continuing service with the Issuer.